Travere misses primary endpoint in PhIII for rare kidney disease but the company is still considering a 'path forward'
Travere Therapeutics’ drug sparsentan didn’t hit the primary endpoint in a Phase III study in a rare kidney disease, but neither the company nor analysts have written it off as a complete failure.
The study looked at sparsentan in focal segmental glomerulosclerosis (FSGS), a rare kidney disease that leads to scarring of the kidney, resulting in proteinuria and rapid decline in kidney function.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.